Skip to content

Study About no Antimicrobial Prophylaxis in Totally Laparoscopic Distal Gastrectomy

Multicenter Randomized Controlled Trial About no Antimicrobial Prophylaxis for Patients Undergoing Totally Laparoscopic Distal Gastrectomy for Gastric Carcinoma (KSWEET-03)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03802097
Acronym
KSWEET-03
Enrollment
260
Registered
2019-01-14
Start date
2018-12-27
Completion date
2022-03-25
Last updated
2022-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complication of Surgical Procedure, Gastric Cancer

Keywords

Gastric cancer, Laparoscopic gastrectomy, Prophylactic antibiotics, Infectious complications

Brief summary

Laparoscopic gastrectomy has fewer infectious complications compared to open surgery. Recently, the incidence of postoperative infectious complications was greatly reduced due to the development of surgical techniques and improvement of prevention and control of surgical infection. Previous multicenter, phase II study (KSWEET-01) revealed that the incidence of infectious complications of laparoscopic gastrectomy without prophylactic antibiotics was not significantly higher than previously reported data. Therefore, this study aim to prove the safety of totally laparoscopic distal gastrectomy without prophylactic antibiotics, specially reference to the postoperative infectious complications.

Detailed description

The purpose of this study was to investigate the non-inferiority of incidence of infectious complications in the experimental group that did not use prophylactic antibiotics compared to the control group using prophylactic antibiotics. The primary endpoint is the incidence of surgical site infections within 30 days after surgery and the difference limit of the non-inferiority of the experimental group is assumed to be - 0.05 (5%). Assuming that the incidence of postoperative infectious complications in the control group is 5% and the incidence of infectious complications in the experimental group is assumed to be about 8%. It is assumed that the significant level is 5% and the power is at least 80%. According to the above method, a total of 260 patients (130 patients in each group) are needed when 117 patients are needed in each group and about 10% of drop rates and protocol violence are considered.

Interventions

PROCEDURENo use of antimicrobial prophylaxis

Do not use of prophylactic antimicrobial for the patients with undergoing totally laparoscopic distal gastrectomy with D1 or D1+ lymphadenectomy for the gastric cancer

PROCEDUREUse of antimicrobial prophylaxis

Use of prophylactic antimicrobial for the patients with undergoing totally laparoscopic distal gastrectomy with D1 or D1+ lymphadenectomy for the gastric cancer

Sponsors

Korean South West East Gastric Surgery Group
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* A patient undergoing totally laparoscopic distal gastrectomy for the gastric cancer located in the low or middle part of the stomach * A patient who underwent limited lymphadenectomy (D1 or D1+) with clinical T1-2N0M0 stage based on 8th edition of the International Union Against Cancer (UICC) tumor node metastasis (TNM) classification * From 18 to 75 years old * Eastern Cooperative Oncology Group (ECOG) status 0-1 * American Society of Anesthesiologists (ASA) score I-II * A patient with appropriate bone marrow function, renal function, lung function, and liver function * Before the surgery, decide to participate in this study and agree with the written informed consent

Exclusion criteria

* A patient who underwent previous abdominal surgery * Combined other abdominal organ cancer * A patient who received chemotherapy and radiotherapy within the last 6 months * Combined organ resection other than cholecystectomy * A patient undergoing emergency surgery due to perforation or bleeding * A patient who have received antibiotic treatment for other infectious diseases within one month of operation * Severely malnourished patient

Design outcomes

Primary

MeasureTime frameDescription
Incidence of surgical site infections within 30 dayswithin 30 days after operationThe diagnosis of infectious complications is made according to the Centers for Disease Control and Prevention (CDC) surgical site infection diagnosis criteria according to physical or radiological findings.

Secondary

MeasureTime frameDescription
Length of hospital stayup to 6 monthsFrom date of operation until the date of hospital discharge
Incidence of remote non-surgical site infectionswithin 30 days after operationAny postoperative infectious complications other than surgical site infections

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026